Sample size for a noninferiority clinical trial with time-to-event data in the presence of competing risks

被引:2
|
作者
Han, Dong [1 ,2 ]
Chen, Zheng [1 ]
Hou, Yawen [3 ]
机构
[1] Southern Med Univ, Sch Publ Hlth, Dept Biostat, Guangdong Prov Key Lab Trop Dis Res, Guangzhou, Guangdong, Peoples R China
[2] Southern Med Univ, Dept Qual Control, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China
[3] Jinan Univ, Dept Stat, Coll Econ, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Competing risks; Noninferiority clinical trials; sample size; sub-distribution hazard ratio; survival data; END-POINTS; MULTISTATE MODELS; FOLLOW-UP; PITFALLS; CANCER;
D O I
10.1080/10543406.2017.1399897
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The analysis and planning methods for competing risks model have been described in the literature in recent decades, and noninferiority clinical trials are helpful in current pharmaceutical practice. Analytical methods for noninferiority clinical trials in the presence of competing risks (NiCTCR) were investigated by Parpia et al., who indicated that the proportional sub-distribution hazard (SDH) model is appropriate in the context of biological studies. However, the analytical methods of the competing risks model differ from those appropriate for analyzing noninferiority clinical trials with a single outcome; thus, a corresponding method for planning such trials is necessary. A sample size formula for NiCTCR based on the proportional SDH model is presented in this paper. The primary endpoint relies on the SDH ratio. A total of 120 simulations and an example based on a randomized controlled trial verified the empirical performance of the presented formula. The results demonstrate that the empirical power of sample size formulas based on the Weibull distribution for noninferiority clinical trials with competing risks can reach the targeted power.
引用
收藏
页码:797 / 807
页数:11
相关论文
共 50 条
  • [1] Sample sizes for clinical trials with time-to-event endpoints and competing risks
    Schulgen, G
    Olschewski, M
    Krane, V
    Wanner, C
    Ruf, G
    Schumacher, M
    [J]. CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 386 - 396
  • [2] Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time
    Phadnis, Milind A.
    Mayo, Matthew S.
    [J]. JOURNAL OF APPLIED STATISTICS, 2021, 48 (06) : 1009 - 1032
  • [3] Competing risks analysis for discrete time-to-event data
    Schmid, Matthias
    Berger, Moritz
    [J]. WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL STATISTICS, 2021, 13 (05)
  • [4] Competing risks analysis of time-to-event data for cardiovascular surgeons
    Staffa, Steven J.
    Zurakowski, David
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2020, 159 (06): : 2459 - +
  • [5] Number needed to treat for time-to-event data with competing risks
    Gouskov, Natalia A.
    Kundu, Suprateek
    Imrey, Peter B.
    Fine, Jason P.
    [J]. STATISTICS IN MEDICINE, 2014, 33 (02) : 181 - 192
  • [6] Validation of discrete time-to-event prediction models in the presence of competing risks
    Heyard, Rachel
    Timsit, Jean-Francois
    Held, Leonhard
    [J]. BIOMETRICAL JOURNAL, 2020, 62 (03) : 643 - 657
  • [7] Longitudinal mediation analysis of time-to-event endpoints in the presence of competing risks
    Tat-Thang Vo
    Hilary Davies-Kershaw
    Ruth Hackett
    Stijn Vansteelandt
    [J]. Lifetime Data Analysis, 2022, 28 : 380 - 400
  • [8] Quantifying the predictive accuracy of time-to-event models in the presence of competing risks
    Schoop, Rotraut
    Beyersmann, Jan
    Schumacher, Martin
    Binder, Harald
    [J]. BIOMETRICAL JOURNAL, 2011, 53 (01) : 88 - 112
  • [9] Longitudinal mediation analysis of time-to-event endpoints in the presence of competing risks
    Tat-Thang Vo
    Davies-Kershaw, Hilary
    Hackett, Ruth
    Vansteelandt, Stijn
    [J]. LIFETIME DATA ANALYSIS, 2022, 28 (03) : 380 - 400
  • [10] Impact of the censoring distribution on time-to-event problems in the presence of competing risks
    Mark W Donoghoe
    Val Gebski
    [J]. Trials, 12 (Suppl 1)